Elamipretide

依拉瑞肽

Report date: 2026/02/04 15:16:01
NME

Base Information

Drug NameElamipretide
Drug Alias NameElamipretide - Stealth BioTherapeutics依拉雷肽Elamipretide-hydrochloride - Stealth BiotherapeuticsElamipretide-hydrochlorideElamipretidum +[15] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMitocliondrial permeability transition pore inhibitorsFree radicals scavengersCardiolipin modulators
TargetsMitocliondrial permeability transition poreFree radicals
Therapy Area/IndicationsDiabetic macular oedemaHealthy AgingMitochondrial Diseases +[14] 
Global Approved IndicationsBarth Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/09/19
Country/TerritoryCzechiaBelgiumBulgaria +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCornell UniversityInstitut De Recherches Cliniques De Montreal (Ircm)
China Registration ClassN/A

Develop Information

Active CompaniesPharmanoviaStealth Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsHealthy AgingMitochondrial DiseasesBarth Syndrome +[6] 
Inactive IndicationsDiabetic macular oedemaReperfusion InjuryST Elevation Myocardial Infarction +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG